On August 24, 2020, the Company announced that it completed a merger with Mosaic ImmunoEngineering Inc., ("Mosaic"), a private biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, through the issuance of convertible preferred stock. The merged company will focus on advancing its immunotherapy pipeline of products, including intra-tumoral immunotherapy of cancer and its modular vaccine platform.